H.C. Wainwright raised the firm’s price target on X4 Pharmaceuticals to $5 from $3 and keeps a Buy rating on the shares after the FDA approved mavorixafor, to be marketed as Xolremdi, for the treatment of WHIM syndrome in patients 12 years of age and older.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- X4 Pharmaceuticals: XOLREMDI FDA Approval and Launch Update
- X4 Pharmaceuticals Launches XOLREMDI with FDA Approval
- X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
- Biotech Alert: Searches spiking for these stocks today
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
